Market capitalization | $1.47m |
Enterprise Value | $25.29m |
P/E (TTM) P/E ratio | negative |
EV/FCF (TTM) EV/FCF | negative |
EV/Sales (TTM) EV/Sales | 45.98 |
P/S ratio (TTM) P/S ratio | 2.67 |
P/B ratio (TTM) P/B ratio | negative |
Revenue growth (TTM) Revenue growth | -82.94% |
Revenue (TTM) Revenue | $550.00k |
As a Free StocksGuide user, you can view scores for all 6,883 stocks worldwide.
2 Analysts have issued a Trevena, Inc. forecast:
2 Analysts have issued a Trevena, Inc. forecast:
Sep '24 |
+/-
%
|
||
Revenue | 0.55 0.55 |
83%
83%
|
|
Gross Profit | -1.54 -1.54 |
183%
183%
|
|
EBITDA | -32 -32 |
6%
6%
|
EBIT (Operating Income) EBIT | -32 -32 |
7%
7%
|
Net Profit | -34 -34 |
11%
11%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Trevena, Inc. engages in the development and commercialization of novel medicines for patients affected by central nervous system disorders. Its product candidates include Oliceridine injection, TRV250, TRV734, and TRV045. The company was founded by Maxine Gowen, Robert Joseph Lefkowitz, Scott DeWire, Howard A. Rockman, Jonathan Violin, and Erin Whalen on November 9, 2007 and is headquartered in Chesterbrook, PA.
Head office | United States |
CEO | Carrie Bourdow |
Employees | 23 |
Founded | 2007 |
Website | www.trevena.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.